LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Strona główna・Stock List・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Closed

SectorHealthcare

21.17 -5.41

Buy Sell

Overview

Share price change

24h

Current

Min

21.05

Max

22.16

Key metrics
By Trading Economics
Income	10M 17M
Sales	30M 130M
EPS	0.13
Profit margin	13.432
Employees	354
EBITDA	11M 22M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+50.97% upside

Dividends
By Dow Jones
Next Earnings	5 maj 2026

Market Stats
By TradingEconomics
Market Cap	-458M 2.8B
Previous open	26.58
Previous close	21.17

News Sentiment

By Acuity

50%

164 / 349 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

12.42 / 14.93 Support & Resistance

Arcutis Biotherapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 mar 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Peace Talks -- Market Talk

26 mar 2026, 23:36 UTC

Market Talk

Major News Events

Gold Rises Amid Signs of Easing Middle East Tensions -- Market Talk

26 mar 2026, 23:35 UTC

Acquisitions, Mergers, Takeovers

Pernod Ricard: Confirms Discussions With Brown-Forman

26 mar 2026, 23:29 UTC

Earnings

Haier Smart Home: Company to Finance Share Buybacks Via Internal Funds >600690.SH

26 mar 2026, 23:28 UTC

Earnings

Haier Smart Home Plans A Share Buybacks of CNY3.0B-CNY6.0B >600690.SH

26 mar 2026, 23:28 UTC

Earnings

Haier Smart Home Plans to Increase Payout Ratio to 60% for 2027, 2028 >600690.SH

26 mar 2026, 23:28 UTC

Earnings

Haier Smart Home Plans Cash Dividend Payout Ratio of Up to 58% for 2026 >600690.SH

26 mar 2026, 23:27 UTC

Earnings

Haier Smart Home 2025 Net CNY19.55B Vs. Net CNY18.73B >600690.SH

26 mar 2026, 23:27 UTC

Earnings

Haier Smart Home 2025 Rev CNY302.33B Vs. CNY286.01B >600690.SH

26 mar 2026, 23:08 UTC

Market Talk

Infratil's Investor Day Addresses Data-Center Issues -- Market Talk

26 mar 2026, 23:04 UTC

Acquisitions, Mergers, Takeovers

Pernod Ricard in Talks to Combine With Jack Daniel's Maker Brown-Forman -- WSJ

26 mar 2026, 23:04 UTC

Acquisitions, Mergers, Takeovers

Families Behind Pernod, Brown-Forman Would Each Likely Retain Significant Stakes, Source Says -- WSJ

26 mar 2026, 23:04 UTC

Acquisitions, Mergers, Takeovers

Pernod, Brown-Forman Discussing Mostly Stock Deal, Source Says -- WSJ

26 mar 2026, 23:04 UTC

Acquisitions, Mergers, Takeovers

Pernod-Brown-Forman Deal Announcement Could Be Weeks Away, Sources Say -- WSJ

26 mar 2026, 23:04 UTC

Acquisitions, Mergers, Takeovers

Pernod in Deal Talks With Brown-Forman -- WSJ

26 mar 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Brown-Forman: No Agreement Has Been Reached as to Terms of Any Possible Pernod Ricard Transaction

26 mar 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Brown-Forman: Synergies From Contemplated Pernod Ricard Combination Expected to Be Significant

26 mar 2026, 22:26 UTC

Earnings

Jiangxi Copper 2025 Rev CNY544.62B Vs. CNY516.61B >0358.HK

26 mar 2026, 22:26 UTC

Earnings

Jiangxi Copper 2025 Net CNY7.13B Vs. Net CNY6.96B >0358.HK

26 mar 2026, 22:26 UTC

Earnings

Jiangxi Copper Higher Demand For Products Supported Results>0358.HK

26 mar 2026, 22:08 UTC

Earnings

Air China 2025 Loss CNY1.79B Vs. Loss CNY232.56M >0753.HK

26 mar 2026, 22:08 UTC

Earnings

Air China Impairment Loss on Goodwill Weighed on Results>0753.HK

26 mar 2026, 22:08 UTC

Earnings

Air China 2025 Rev CNY171.48B Vs. CNY166.70B >0753.HK

26 mar 2026, 22:07 UTC

Market Talk

Major News Events

Global Energy Roundup: Market Talk

26 mar 2026, 22:07 UTC

Market Talk

Major News Events

Open-Pit Gold Miners Most Exposed to High Fuel Prices -- Market Talk

26 mar 2026, 22:00 UTC

Earnings

Tsingtao Brewery 2025 Net CNY4.59B Vs. Net CNY4.34B >0168.HK

26 mar 2026, 22:00 UTC

Earnings

Tsingtao Brewery: Higher Volume Sales of Beer Supported Results>0168.HK

26 mar 2026, 22:00 UTC

Earnings

Tsingtao Brewery 2025 Rev CNY32.47B Vs. CNY32.14B >0168.HK

26 mar 2026, 21:39 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Sees Early Indications of Strong Interest in Site Adjacent Western Port

26 mar 2026, 21:38 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Has Begun Expression of Interest Process For 65-Hectare Site Adjacent Western Port

Peer Comparison

Price change

Arcutis Biotherapeutics Inc Forecast

Price Target

By TipRanks

50.97% upside

12 Months Forecast

Average 34.33 USD 50.97%

High 36 USD

Low 31 USD

Based on 9 Wall Street analysts offering 12 month price targets forArcutis Biotherapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Arcutis Biotherapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

12.42 / 14.93Support & Resistance

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentiment

By Acuity

164 / 349 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.